DCF Advisers LLC Acquires 5,000 Shares of Biohaven Ltd. (NYSE:BHVN)

DCF Advisers LLC raised its holdings in shares of Biohaven Ltd. (NYSE:BHVN) by 16.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 36,000 shares of the company’s stock after purchasing an additional 5,000 shares during the quarter. DCF Advisers LLC’s holdings in Biohaven were worth $1,345,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Spire Wealth Management bought a new stake in shares of Biohaven during the fourth quarter worth $56,000. KBC Group NV raised its holdings in shares of Biohaven by 24.5% in the third quarter. KBC Group NV now owns 2,250 shares of the company’s stock valued at $112,000 after acquiring an additional 443 shares in the last quarter. Amalgamated Bank raised its holdings in shares of Biohaven by 21.9% in the fourth quarter. Amalgamated Bank now owns 2,929 shares of the company’s stock valued at $109,000 after acquiring an additional 527 shares in the last quarter. US Bancorp DE raised its holdings in shares of Biohaven by 36.7% in the fourth quarter. US Bancorp DE now owns 2,971 shares of the company’s stock valued at $111,000 after acquiring an additional 798 shares in the last quarter. Finally, Capstone Investment Advisors LLC bought a new stake in shares of Biohaven in the third quarter valued at about $250,000. 88.78% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. HC Wainwright restated a “buy” rating and issued a $54.00 price objective on shares of Biohaven in a report on Tuesday, March 4th. Royal Bank of Canada restated an “outperform” rating and issued a $61.00 price objective on shares of Biohaven in a report on Tuesday, March 4th. Deutsche Bank Aktiengesellschaft assumed coverage on Biohaven in a report on Tuesday, February 11th. They issued a “buy” rating and a $65.00 price objective for the company. Morgan Stanley decreased their price objective on Biohaven from $69.00 to $63.00 and set an “overweight” rating for the company in a report on Friday, March 7th. Finally, JPMorgan Chase & Co. cut their target price on Biohaven from $72.00 to $68.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 5th. Fourteen equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $63.15.

Insider Activity at Biohaven

In other news, Director John W. Childs bought 29,000 shares of the company’s stock in a transaction that occurred on Monday, December 30th. The shares were purchased at an average price of $35.94 per share, for a total transaction of $1,042,260.00. Following the completion of the transaction, the director now directly owns 2,368,741 shares in the company, valued at approximately $85,132,551.54. This represents a 1.24 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. 16.00% of the stock is owned by insiders.

Biohaven Stock Performance

Shares of BHVN stock opened at $28.16 on Friday. Biohaven Ltd. has a fifty-two week low of $26.80 and a fifty-two week high of $60.46. The firm has a market capitalization of $2.87 billion, a price-to-earnings ratio of -3.01 and a beta of 1.27. The stock’s 50-day simple moving average is $36.06 and its 200-day simple moving average is $41.68.

Biohaven (NYSE:BHVN) last issued its quarterly earnings results on Monday, March 3rd. The company reported ($1.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.29). As a group, equities analysts forecast that Biohaven Ltd. will post -8.9 earnings per share for the current year.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.